MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Font ResizerAa
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Reading: Dionysus Health Appoints Digital Health Leader Rashmi Raghavendra as Chief Executive Officer
Share
Font ResizerAa
MarketAlert – Real-Time Market & Crypto News, Analysis & AlertsMarketAlert – Real-Time Market & Crypto News, Analysis & Alerts
Search
  • Crypto News
    • Altcoins
    • Bitcoin
    • Blockchain
    • DeFi
    • Ethereum
    • NFTs
    • Press Releases
    • Latest News
  • Blockchain Technology
    • Blockchain Developments
    • Blockchain Security
    • Layer 2 Solutions
    • Smart Contracts
  • Interviews
    • Crypto Investor Interviews
    • Developer Interviews
    • Founder Interviews
    • Industry Leader Insights
  • Regulations & Policies
    • Country-Specific Regulations
    • Crypto Taxation
    • Global Regulations
    • Government Policies
  • Learn
    • Crypto for Beginners
    • DeFi Guides
    • NFT Guides
    • Staking Guides
    • Trading Strategies
  • Research & Analysis
    • Blockchain Research
    • Coin Research
    • DeFi Research
    • Market Analysis
    • Regulation Reports
Have an existing account? Sign In
Follow US
© Market Alert News. All Rights Reserved.
  • bitcoinBitcoin(BTC)$67,711.000.67%
  • ethereumEthereum(ETH)$1,960.350.86%
  • tetherTether(USDT)$1.000.02%
  • rippleXRP(XRP)$1.431.26%
  • binancecoinBNB(BNB)$626.162.90%
  • usd-coinUSDC(USDC)$1.000.00%
  • solanaSolana(SOL)$84.371.84%
  • tronTRON(TRX)$0.2845420.34%
  • dogecoinDogecoin(DOGE)$0.0999221.28%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.040.64%
Learn

Dionysus Health Appoints Digital Health Leader Rashmi Raghavendra as Chief Executive Officer

Last updated: November 23, 2025 3:35 pm
Published: 3 months ago
Share

New CEO to Lead Company from Groundbreaking Science to Commercial Launch in Maternal Mental Health Diagnostics

SEATTLE, Nov. 22, 2025 /PRNewswire/ — Dionysus Health, a precision diagnostics company revolutionizing maternal mental health through Epigenetics and Artificial Intelligence, today announced the appointment of Rashmi Raghavendra as Chief Executive Officer.

Dionysus Health, today announced the appointment of Rashmi Raghavendra as Chief Executive Officer.

Raghavendra is a globally recognized leader in digital health, diagnostics innovation, and healthcare AI. With more than 20 years of experience transforming early-stage ventures into scalable, revenue-generating companies, she has created over $500 million in healthcare revenue and led major initiatives across Apple, Samsung, Qualcomm, and Philips Healthcare. As Founder and Managing Director of rcubed | ventures, Rashmi has invested in and advised several startups advancing women’s health, predictive diagnostics, and virtual care solutions.

“Rashmi’s appointment marks a transformative milestone for Dionysus Health,” said Dr. Andrea Cubitt, Co-Founder and Board Director. “Her deep expertise in commercialization, healthcare AI, and diagnostics innovation will guide our next chapter as we bring our clinically validated science into real-world impact for mothers everywhere.”

Raghavendra joins Dionysus Health at a pivotal time as the company moves from validated, groundbreaking science to full commercialization. The clinically validated diagnostic tool has demonstrated up to 90% predictive accuracy in over 600 participants. It is supported by $14.5 million in non-dilutive funding from the National Institutes of Health (NIH) and the U.S. Department of Defense (DoD). The company anticipates several key milestones:

First commercial pilots launching in Dec 2025, in Florida with multiple leading OB-GYN groupsFDA Breakthrough Device Designation in 2026Full FDA Device Approval by 2027

Dionysus Health is currently completing its financing efforts to support the upcoming commercial pilots and accelerate regulatory approvals.

“Dionysus Health is redefining what’s possible in maternal mental health,” said Raghavendra. “By harnessing epigenetics and AI, our technology shifts care from reaction to prevention, empowering clinicians to identify risk for postpartum depression as early as 24 weeks into pregnancy. I’m honored to lead this mission and bring proactive care to women and families who’ve waited far too long. As both a mother and a healthcare executive, this work is deeply personal.”

Visit https://dionysushealth.com/ to learn more about Dionysus Health’s innovative approach to maternal mental health and how it plans to make a positive impact on women and families. Explore the company’s research, technology, and mission to revolutionize maternal mental health screening.

About Dionysus Health

Dionysus Health is a precision diagnostics company harnessing AI and epigenetics to predict and prevent postpartum depression before it starts. The company’s proprietary blood test identifies a woman’s risk as early as 24 weeks of pregnancy, using advanced molecular biomarkers and AI-driven pattern recognition to detect biological changes months before symptoms arise. Clinically validated in more than 600 participants with up to 90% predictive accuracy, the diagnostic has been supported by $14.5 million in non-dilutive funding from the National Institutes of Health (NIH) and the U.S. Department of Defense (DoD). Dionysus Health anticipates FDA Breakthrough Device designation in 2026 and full approval by 2027, with its first commercial pilots launching in 2025. Every year, postpartum depression affects one in five new mothers and costs the U.S. more than $14 billion, yet half of all cases go undiagnosed and untreated. Dionysus Health’s mission is simple but profound: to make predictive maternal mental health screening the standard of care, improving outcomes for women, families, and society at large.

Rashmi’s Contact Info:

[email protected]

Rashmi’s LinkedIn

Media Contact: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/dionysus-health-appoints-digital-health-leader-rashmi-raghavendra-as-chief-executive-officer-302623938.html

SOURCE Dionysus Health

Read more on The Grand Junction Daily Sentinel

This news is powered by The Grand Junction Daily Sentinel The Grand Junction Daily Sentinel

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook

Like this:

Like Loading...

Related

U.S. Olympic and Paralympic Committee bans transgender athletes from women’s sports
Greatest Real money Web based casinos Top Within the January 2026
Apple MacBook Pro gets huge £270 discount but stock is running low – The Mirror
Will Nifty break 26,300 and chart a fresh record high this week?
NFL world shocked after Browns cut Pro Bowl quarterback

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Email Copy Link Print
Previous Article 30 years later, ‘GoldenEye’ remains one of the best James Bond movies
Next Article Best Crypto to Buy Now: Low Cap Altcoins to Watch Ahead of 2026
© Market Alert News. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Prove your humanity


Lost your password?

%d